Zensar OBT Technologies Announces Its OBT Pharma Solution is a Qualified SAP Business All-in-One Partner Solution

Share Article

Solution Designed to Meet the Needs of and Improve Performance of Small and Midsize Pharmaceutical Manufacturing Companies

Midsize companies are realizing the value of SAP Business All-in-One solutions that can be rapidly deployed leveraging SAP ERP and proven industry best practices through our qualified partner solutions

Zensar OBT Technologies today announced OBT Pharma, a new business management solution designed specifically to meet the needs and improve the performance of small and midsize pharmaceutical manufacturers. The OBT Pharma solution, which is a qualified SAP® Business All-in-One partner solution, provides pharmaceutical companies with the affordability and expertise of the SAP application while combining the industry knowledge and experience of Zensar OBT Technologies.

Zensar OBT Technologies and its new OBT Pharma solution allows pharmaceutical manufacturing companies to streamline their business processes. Benefits realized include reducing inventory, increased order fulfillment rates, improved visibility into product cost and profitability, as well as increasing cash flow. OBT Pharma provides over 300 business processes required by small and midsize pharmaceutical manufacturing companies, including planning, manufacturing, procurement, warehousing, cash management, a strong foundation for FDA compliance, and reporting.

SAP Business All-in-One partner solutions are qualified by SAP and offer the flexibility to accommodate the unique business needs of each customer. Qualified SAP Business All-in-One partner solutions are preconfigured, industry-specific versions of the SAP ERP application combined with SAP Best Practices offerings, enabling streamlined operations, lower costs and a proven path to growth.    

"Midsize companies are realizing the value of SAP Business All-in-One solutions that can be rapidly deployed leveraging SAP ERP and proven industry best practices through our qualified partner solutions," said, Jim Sabogal, vice president and global IBU director for Life Sciences Industry Solutions Business Unit, SAP Labs, LLC. "With the new OBT Pharma solution, Zensar OBT Technologies enables companies to leverage their expertise in the pharmaceutical industry to achieve their objectives of improved growth, lower costs and a better understanding of business processes."

"By working with SAP, we have successfully enhanced our solution to leverage SAP's strength of integration and the support capabilities of a leading software vendor, while combining our industry experience and our focus on rapid, cost-effective implementation," said Ramesh Kodali, CEO of Zensar OBT Technologies. "This will provide tangible business benefits for our customers."

The combination of Zensar OBT Technology's expertise in the pharmaceutical industry and its vertical business processes with SAP's ongoing industry expertise and proven implementation methodology, OBT Pharma provides customers with a rapidly deployed, easily managed enterprise software solution for improved business processes, rapid deployment, and tangible business benefits.

About Zensar OBT Technologies
Zensar OBT Technologies, a leading SAP service provider for over 10 years, is a subsidiary of Zensar Technologies, a global IT and BPO services provider. Our industry expertise in verticals such as Textile, Apparel and Footwear, Life Sciences, Chemicals, Engineering, Food, Retail, and Manufacturing plus proven implementation experience makes it an automatic choice for many CIO's looking at rapidly deploying SAP and reaping business benefits in shorter timeframes.

SAP and all SAP logos are trademarks or registered trademarks of SAP AG in Germany and in several other countries.
All other product and service names mentioned are the trademarks of their respective companies.

SAP Forward-looking Statement (Only include if an SAP quote is included.)
Any statements contained in this document that are not historical facts are forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions as they relate to SAP are intended to identify such forward-looking statements. SAP undertakes no obligation to publicly update or revise any forward-looking statements. All forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from expectations The factors that could affect SAP's future financial results are discussed more fully in SAP's filings with the U.S. Securities and Exchange Commission ("SEC"), including SAP's most recent Annual Report on Form 20-F filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates.

For more information, Zensar OBT Technologies, Inc.
Ramesh Kodali
CEO Zensar OBT Technologies
609-452-1414 x3009
Rameshk @ zensar.com

For more information, visit our website at: http://www.zensar.com


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Paul Grillo
Visit website